OBJECTIVE: To identify the CD44-receptor-mediated effects of 5-7 x 10(5)MW hyaluronan (HA, Hyalgan) on cell viability in normal and damaged human chondrocyte primary cultures isolated from articular cartilage. DESIGN: Primary cultures of human chondrocytes were established from normal articular biopsies and expanded to the second culture passage. The dose-response effects of HA on the viability of normal cultures were identified. Chondrocytes were then treated with either hypoxanthine (2 mM) and xanthine oxidase (20-60 mU), or with activated polymorphonuclear leukocytes (PMNs) to induce injury. Damaged and control cells were then treated with 5-7 x 10(5)HA in the previously identified optimal dose of 0.05 mg/ml. Viability was assessed at specific time periods for the chemically and PMN-damaged cells. To identify if HA effects were mediated by the CD44 receptor, chondrocytes were incubated with anti-CD44 antibody at saturating concentrations (5 microg/ml for 100,000 cells) to produce a maximum inhibition of HA binding. Cells were evaluated using the MTT viability assay, histology, electron microscopy and immunohistochemistry. RESULTS: Direct addition of HA (optimal dose, 0.5 mg/ml) significantly increased cell survival in normal chondrocyte primary cultures (P<0.05). Similarly, addition of this same dose of HA to cultures of free radical-damaged chondrocytes, restored the viability to baseline conditions. Cell viability rates dropped significantly (P<0.05) when CD44 receptor binding was inhibited, indicating that cell growth was mediated by the CD44 receptor. CONCLUSIONS: HA (0.5 mg/ml of 5-7 x 10(5)) significantly increased the viability of normal human chondrocytes in primary culture and restored cell viability to near normal levels after oxidative cell injury.
OBJECTIVE: To identify the CD44-receptor-mediated effects of 5-7 x 10(5)MW hyaluronan (HA, Hyalgan) on cell viability in normal and damaged human chondrocyte primary cultures isolated from articular cartilage. DESIGN: Primary cultures of human chondrocytes were established from normal articular biopsies and expanded to the second culture passage. The dose-response effects of HA on the viability of normal cultures were identified. Chondrocytes were then treated with either hypoxanthine (2 mM) and xanthine oxidase (20-60 mU), or with activated polymorphonuclear leukocytes (PMNs) to induce injury. Damaged and control cells were then treated with 5-7 x 10(5)HA in the previously identified optimal dose of 0.05 mg/ml. Viability was assessed at specific time periods for the chemically and PMN-damaged cells. To identify if HA effects were mediated by the CD44 receptor, chondrocytes were incubated with anti-CD44 antibody at saturating concentrations (5 microg/ml for 100,000 cells) to produce a maximum inhibition of HA binding. Cells were evaluated using the MTT viability assay, histology, electron microscopy and immunohistochemistry. RESULTS: Direct addition of HA (optimal dose, 0.5 mg/ml) significantly increased cell survival in normal chondrocyte primary cultures (P<0.05). Similarly, addition of this same dose of HA to cultures of free radical-damaged chondrocytes, restored the viability to baseline conditions. Cell viability rates dropped significantly (P<0.05) when CD44 receptor binding was inhibited, indicating that cell growth was mediated by the CD44 receptor. CONCLUSIONS: HA (0.5 mg/ml of 5-7 x 10(5)) significantly increased the viability of normal human chondrocytes in primary culture and restored cell viability to near normal levels after oxidative cell injury.
Authors: Sen Liu; Qing-Song Zhang; William Hester; Michael J O'Brien; Felix H Savoie; Zongbing You Journal: Am J Sports Med Date: 2012-03-16 Impact factor: 6.202
Authors: E Kon; G Filardo; D Robinson; J A Eisman; A Levy; K Zaslav; J Shani; N Altschuler Journal: Knee Surg Sports Traumatol Arthrosc Date: 2013-03-12 Impact factor: 4.342
Authors: Valentina Grishko; Min Xu; Renee Ho; Aaron Mates; Scott Watson; Jong T Kim; Glenn L Wilson; Albert W Pearsall Journal: J Biol Chem Date: 2009-02-04 Impact factor: 5.157
Authors: T Yatabe; S Mochizuki; M Takizawa; M Chijiiwa; A Okada; T Kimura; Y Fujita; H Matsumoto; Y Toyama; Y Okada Journal: Ann Rheum Dis Date: 2008-07-28 Impact factor: 19.103
Authors: Paola Brun; Sally C Dickinson; Barbara Zavan; Roberta Cortivo; Anthony P Hollander; Giovanni Abatangelo Journal: Arthritis Res Ther Date: 2008-11-11 Impact factor: 5.156
Authors: A Migliore; E Bizzi; O De Lucia; A Delle Sedie; M Bentivegna; Asmaa Mahmoud; C Foti Journal: Clin Med Insights Arthritis Musculoskelet Disord Date: 2016-05-25